Damora Therapeutics
DMRA
19 hedge funds and large institutions have $175M invested in Damora Therapeutics in 2020 Q4 according to their latest regulatory filings, with 19 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
55.85% more ownership
Funds ownership: 0% → 55.85% (+56%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$60.9M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$37.2M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$32M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$22.5M |
| 5 |
Janus Henderson Group
London,
|
+$19.9M |
Top Sellers
DMRA Hedge Fund Activity: Q4 2020 in Review
19 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics (DMRA) for Q4 2020, worth a combined $175M.
Buyers outnumbered sellers: 19 funds opened new DMRA positions and 0 closed out — a net gain of 19 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $60.9M.
- 19 institutional investors held Damora Therapeutics (DMRA) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $175M of Damora Therapeutics stock for Q4 2020.
- 19 funds opened new Damora Therapeutics positions in Q4 2020 and 0 closed out, a net change of +19 holders.
- The largest Damora Therapeutics buyer in Q4 2020 was OrbiMed, an estimated $60.9M added.
Based on aggregated 13F filings for Q4 2020.